Lupus Foundation of America1mon
New Study Finds Anifrolumab In Addition to Standard of Care Treatment is Effective at Reducing Organ Damage Accumulation
A recent study evaluated the effectiveness of anifrolumab (Saphnelo®) combined with standard of care (SOC) treatments compared to SOC treatment alone in preventing organ damage. Results showed that ...
pharmaphorum3y
FDA approves AZ's anifrolumab, ending 10-year lupus drug drought
Anifrolumab was all-but written off in 2018 after failing the phase 3 TULIP-1 trial, but bounced back with positive data from a second study – TULIP-2 – that has proved sufficient for the FDA ...
Renal & Urology News27d
Anifrolumab Tied to Less Organ Damage for Patients With Lupus
Zahi Touma, MD, PhD, from the University Health Network in Toronto, and colleagues examined whether anifrolumab plus SOC is associated with reduced organ damage accumulation compared with SOC only ...
pharmaphorum3d
AZ fleshes out positive trial of revitalised lupus drug anifrolumab
After being all-but written off a year ago, AstraZeneca’s anifrolumab has been reborn with new data that suggest it could help to end a drought in treatments for autoimmune disease systemic ...
Monthly Prescribing Reference1mon
Anifrolumab Tied to Less Organ Damage for Patients With Lupus
The likelihood of experiencing an increase in Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index within 208 weeks was lower for patients in the ...